Material Event (Form 8-K)

As previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on August 18, 2026, BioMarin Pharmaceutical Inc., a Delaware corporation ("BioMarin"), entered into a Share Purchase Agreement (the "Purchase Agreement") with (i) Alesta Therapeutics B.V., a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) ("Alesta"), (ii) each of the holders of shares of Alesta identified on Schedule 1.1(a) to the Purchase Agreement, (iii) Anaheim SpinCo B.V., a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid), and (iv) Shareholder Representative Services LLC, solely in its capacity as the representative and attorney-in-fact of the Company Participating Equityholders (as defined in the Purchase Agreement), providing for BioMarin's acquisition of Alesta via a share purchase transaction (the "Share Purchase").

On August 31, 2026, the parties to the Purchase Agreement completed the Share Purchase and, as a result, Alesta is now a wholly owned subsidiary of BioMarin.

The foregoing description of the Purchase Agreement and the transactions contemplated thereby (including the Share Purchase) does not purport to be complete and is subject to, and qualified in its entirety by, the text of the Purchase Agreement, a copy of which is filed as Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the SEC on August 18, 2026 and the terms of which are incorporated herein by reference.